Milestone Pharmaceuticals Q1 EPS $(0.35) Beats $(0.40) Estimate; Cash Balance Of $101M Together With Strategic March 2023 Financing, Expected To Fund Operations Into Mid-2025

Benzinga · 05/11/2023 11:20
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.40) by 12.5 percent. This is a 6.06 percent decrease over losses of $(0.33) per share from the same period last year.